摘要
2022年,肾脏病领域取得了很多重要进展,其中随机对照试验(RCT)仍是临床关注的焦点。本文主要总结2022年肾脏病领域的重要RCT研究结果。
In 2022,a lot of important progress has been made in the field of kidney disease,among which the randomized controlled trial(RCT)is still the focus of clinical attention.This paper mainly summarizes the important RCT research results in the field of kidney disease in 2022.
作者
黄湘华
章海涛
刘志红
HUANG Xianghua;ZHANG Haitao;LIU Zhihong(National Clinical Research Center of Kidney Diseases,Jinling Hospital,Nanjing University School of Medicine,Nanjing 210016,China)
出处
《肾脏病与透析肾移植杂志》
CAS
CSCD
北大核心
2023年第1期49-52,共4页
Chinese Journal of Nephrology,Dialysis & Transplantation
基金
国家重点研发计划(2021YFC2501302)。
关键词
随机对照试验
肾脏疾病
randomized controlled trial
kidney disease
